Cargando…

Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab

BACKGROUND: There is a need to develop biomarkers for a more efficient use of immune checkpoint inhibitors (ICIs). Recently, it has been reported that peripheral blood components, including eosinophils, may be effective ICI biomarkers. This study was designed to evaluate the prognostic value of eosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Shinsuke, Abe, Tomoe, Endo, Tentaro, Kaya, Haruka, Kitabayashi, Takuro, Kawasaki, Yohei, Yamada, Takechiyo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704394/ https://www.ncbi.nlm.nih.gov/pubmed/36452436 http://dx.doi.org/10.2147/CMAR.S382771

Ejemplares similares

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Suzuki, Shinsuke, et al.
Publicado: (2021)

18F-FDG-PET/CT can be used to predict distant metastasis in hypopharyngeal squamous cell carcinoma
por: Suzuki, Shinsuke, et al.
Publicado: (2022)

Irradiated fibroblasts increase interleukin-6 expression and induce migration of head and neck squamous cell carcinoma
por: Suzuki, Shinsuke, et al.
Publicado: (2022)

CD98hc as a marker of radiotherapy-resistant cancer stem cells in head and neck squamous cell carcinoma
por: Kawasaki, Yohei, et al.
Publicado: (2020)

LAT1 is associated with poor prognosis and radioresistance in head and neck squamous cell carcinoma
por: Kawasaki, Yohei, et al.
Publicado: (2023)

GPNMB-Positive Cells in Head and Neck Squamous Cell Carcinoma—Their Roles in Cancer Stemness, Therapy Resistance, and Metastasis
por: Kawasaki, Yohei, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocytes are Prognostic Factors and Can Be Markers of Sensitivity to Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma
por: Suzuki, Hitomi, et al.
Publicado: (2022)

Eotaxin-3 as a Plasma Biomarker for Mucosal Eosinophil Infiltration in Chronic Rhinosinusitis
por: Yamada, Takechiyo, et al.
Publicado: (2019)

SDF-1/CXCR4 induces cell invasion through CD147 in squamous cell carcinoma of the hypopharynx
por: Toyoma, Satoshi, et al.
Publicado: (2020)

The investigation of salvage endoscopic laryngopharyngeal surgery after chemoradiotherapy
por: Kawasaki, Yohei, et al.
Publicado: (2020)

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
por: Tucker, Matthew D., et al.
Publicado: (2021)

Intrinsic Oncogenic Function of Intracellular Connexin26 Protein in Head and Neck Squamous Cell Carcinoma Cells
por: Iikawa, Nobuko, et al.
Publicado: (2018)

An investigation on endoscopic laryngopharyngeal surgery and related outcomes
por: Kawasaki, Yohei, et al.
Publicado: (2018)

Predictive Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Head and Neck Squamous Cell Carcinoma
por: Chen, Miao-Fen, et al.
Publicado: (2018)

Galectin-10 as a Potential Biomarker for Eosinophilic Diseases
por: Tomizawa, Hiroki, et al.
Publicado: (2022)

Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines
por: Gil, Lucia, et al.
Publicado: (2022)

Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis
por: Yu, Yalian, et al.
Publicado: (2018)

Prognostic Relevance of Pretreatment Peripheral Neutrophil Count and Neutrophil-to-lymphocyte Ratio in Primary Cutaneous Angiosarcoma
por: AWAJI, Kentaro, et al.
Publicado: (2021)

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2020)

Neutrophil‐to‐lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non‐small‐cell lung cancer
por: Takeda, Takayuki, et al.
Publicado: (2018)

The evaluation of pretreatment neutrophil–lymphocyte ratio and derived neutrophil–lymphocyte ratio in patients with laryngeal neoplasms()
por: Eskiizmir, Gorkem, et al.
Publicado: (2018)

Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab
por: Watanabe, Hirofumi, et al.
Publicado: (2020)

Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer
por: Gannichida, Ako, et al.
Publicado: (2022)

Investigation of Cry J1 and Cry J2 Concentrations in Japanese Cedar Pollen and Non-Pollen Seasons
por: Tomizawa, Hiroki, et al.
Publicado: (2022)

Eosinophilic fasciitis in association with nivolumab: The importance of eosinophilia
por: Pabón-Cartagena, Gabriela, et al.
Publicado: (2020)

Nivolumab: Acute eosinophilic pneumonia: case report
Publicado: (2022)

Efficacy of Arytenoidectomy after Suture Lateralisation Failure in Patients with Bilateral Vocal Cord Paralysis
por: Suzuki, Shinsuke, et al.
Publicado: (2020)

Optimal cutoff of pretreatment neutrophil-to-lymphocyte ratio in head and neck cancer patients: a meta-analysis and validation study
por: Cho, Jae-Keun, et al.
Publicado: (2018)

Mean level of pretreatment neutrophil to lymphocyte ratio in patients with squamous cell carcinoma of the head and neck–Cross-sectional study
por: Khan, Saqib Raza, et al.
Publicado: (2023)

Role of combining neutrophil-to-lymphocyte ratio and pretreatment body mass index in predicting progression-free survival in patients with non-small cell lung cancer treated with nivolumab
por: Dragomir, Radu, et al.
Publicado: (2021)

Eosinophilic and non-eosinophilic COPD patients with chronic respiratory failure: neutrophil-to-lymphocyte ratio as an exacerbation marker
por: Acartürk Tunçay, Eylem, et al.
Publicado: (2017)

The Correlation of Neutrophil–Lymphocyte Ratio and Eosinophil Count with SCORTEN in SJS/TEN
por: Primisawitri, Pratiwi Prasetya, et al.
Publicado: (2022)

Nivolumab-induced eosinophilic fasciitis: a case report
por: Ollier, Natasha, et al.
Publicado: (2020)

Nivolumab-induced multiple morphea associated with eosinophilic fasciitis
por: Lacombe, Marouschka, et al.
Publicado: (2022)

Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma
por: Najjar, Marc, et al.
Publicado: (2018)

Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Pediatric Parotid Cancer
por: Seng, Dongjie, et al.
Publicado: (2019)

Prognostic Utility of Pretreatment Neutrophil-Lymphocyte Ratio in Advanced Larynx Cancer
por: Kotha, Nikhil V, et al.
Publicado: (2021)

Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide
por: Kumano, Yohei, et al.
Publicado: (2019)

How to detect eosinophil ETosis (EETosis) and extracellular traps
por: Fukuchi, Mineyo, et al.
Publicado: (2021)

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
por: Nakamura, Yoshio, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f3hoqrovbomdhlmdm1du6hpjnh